Vandenberg CJ - Search Results

1

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

Ho GY, Vandenberg CJ, Lim R, Christie EL, Garsed DW, Lieschke E, Nesic K, Kondrashova O, Ratnayake G, Radke M, Penington JS, Carmagnac A, Heong V, Kyran EL, Zhang F, Traficante N; Australian Ovarian Cancer Study; Huang R, Dobrovic A, Swisher EM, McNally O, Kee D, Wakefield MJ, Papenfuss AT, Bowtell DDL, Barker HE, Scott CL. Ho GY, et al. Among authors: vandenberg cj. Ther Adv Med Oncol. 2023 Nov 22;15:17588359231208674. doi: 10.1177/17588359231208674. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028140 Free PMC article.

2

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. van Delft MF, et al. Among authors: vandenberg cj. Cancer Cell. 2006 Nov;10(5):389-99. doi: 10.1016/j.ccr.2006.08.027. Cancer Cell. 2006. PMID: 17097561 Free PMC article.

3

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.

Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, Roberts AW. Mason KD, et al. Among authors: vandenberg cj. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6. doi: 10.1073/pnas.0809957105. Epub 2008 Nov 11. Proc Natl Acad Sci U S A. 2008. PMID: 19004807 Free PMC article.

4

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.

Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, Metcalf D, Scott CL, Cory S. Campbell KJ, et al. Among authors: vandenberg cj. Blood. 2010 Oct 28;116(17):3197-207. doi: 10.1182/blood-2010-04-281071. Epub 2010 Jul 14. Blood. 2010. PMID: 20631380 Free PMC article.

5

Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death.

Michalak EM, Vandenberg CJ, Delbridge AR, Wu L, Scott CL, Adams JM, Strasser A. Michalak EM, et al. Among authors: vandenberg cj. Genes Dev. 2010 Aug 1;24(15):1608-13. doi: 10.1101/gad.1940110. Genes Dev. 2010. PMID: 20679396 Free PMC article.

6

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.

Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ, Dewson G, Michalak EM, Vandenberg CJ, Smyth GK, Strasser A, Cory S, Scott CL. Happo L, et al. Among authors: vandenberg cj. Blood. 2010 Dec 9;116(24):5256-67. doi: 10.1182/blood-2010-04-280818. Epub 2010 Sep 9. Blood. 2010. PMID: 20829369 Free PMC article.

7

DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa.

Kerr JB, Hutt KJ, Michalak EM, Cook M, Vandenberg CJ, Liew SH, Bouillet P, Mills A, Scott CL, Findlay JK, Strasser A. Kerr JB, et al. Among authors: vandenberg cj. Mol Cell. 2012 Nov 9;48(3):343-52. doi: 10.1016/j.molcel.2012.08.017. Epub 2012 Sep 20. Mol Cell. 2012. PMID: 23000175 Free PMC article.

8

DNA repair processes are critical mediators of p53-dependent tumor suppression.

Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, Mizutani S, Brennan MS, Schenk RL, Lindqvist LM, Papenfuss AT, O'Connor L, Strasser A, Herold MJ. Janic A, et al. Among authors: vandenberg cj. Nat Med. 2018 Jul;24(7):947-953. doi: 10.1038/s41591-018-0043-5. Epub 2018 Jun 11. Nat Med. 2018. PMID: 29892060

9

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors.

Xu Z, Vandenberg CJ, Lieschke E, Di Rago L, Scott CL, Majewski IJ. Xu Z, et al. Among authors: vandenberg cj. Mol Cancer Res. 2021 Aug;19(8):1350-1360. doi: 10.1158/1541-7786.MCR-20-0791. Epub 2021 Apr 16. Mol Cancer Res. 2021. PMID: 33863812

10

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Nesic K, et al. Among authors: vandenberg cj. Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28. Cancer Res. 2021. PMID: 34321239

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page